Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on March 16, 2012. The report details the entry into a material definitive agreement regarding a public offering of common stock. Note: The request metadata lists "ACHIEVE LIFE SCIENCES, INC.", but the filing text explicitly identifies the registrant as OncoGenex Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
- Offering Size: Up to 4,165,000 shares of common stock.
- Offering Price: $12.00 per share.
- Gross Proceeds: Approximately $50 million (before underwriting discounts, commissions, and expenses).
- Overallotment Option: Underwriters granted a 30-day option to purchase an additional 624,750 shares.
- Expected Closing: On or about March 21, 2012.
The filing does not provide specific data on historical revenue, profit, cash flow, margins, debt, or liquidity metrics for the company.
Material Changes
The primary material change reported is the execution of an Underwriting Agreement with Leerink Swann LLC and Stifel, Nicolaus & Company, Incorporated. This represents a significant capital raise event intended to increase the company's cash resources.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the intention to complete the public offering. Management notes that actual results may differ materially due to risks including the ability to successfully manage and complete the offering, general economic conditions, and market factors. The company undertakes no obligation to update these statements. The transaction is subject to customary closing conditions.
Investor Verification Checklist
- Verify the final closing date and actual number of shares sold, including any exercise of the overallotment option.
- Confirm the net proceeds received after deducting underwriting discounts, commissions, and offering expenses.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and representations.
- Check subsequent filings for the use of proceeds and any impact on the company's capital structure.